4/15/2025

Johnson & Johnson on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.

Source: Yahoo

4/2/2025

Johnson & Johnson (JNJ) expects its pending acquisition of Intra-Cellular Therapies (ITCI) to have a

Source: Yahoo

3/27/2025

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

3/27/2025

Source: SeekingAlpha

3/20/2025

Navigate market volatility with defensive stocks, bonds, and gold.

Source: SeekingAlpha

3/18/2025

Intra-Cellular Therapies Inc: * INTRA-CELLULAR THERAPIES- ON FEB 26, STOCKHOLDER FILEDLAWSUITAGAINST CO AND BOARD IN NEW YORK SUPREME COURT - SEC FILING * INTRA-CELLULAR...

Source: Finnhub

3/18/2025

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies […]

Source: Yahoo

3/16/2025

In a volatile fourth quarter, the Wasatch Ultra Growth Fund—Investor Class returned 0.94% and slightly underperformed the benchmark Russell 2000® Growth Index, which rose 1.70%.

Source: SeekingAlpha

3/15/2025

Stay ahead with Seeking Alpha's Wall Street Week Ahead! Get key insights on upcoming events, earnings, IPOs, and market trends to make informed decisions.

Source: SeekingAlpha

3/14/2025

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.

Source: Yahoo

3/8/2025

This week's earnings include retailers like Dick’s Sporting Goods, Dollar General, and Kohl’s. Investors will look for Feb. CPI reading that is due Wednesday. See more.

Source: SeekingAlpha

3/5/2025

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.

Source: SeekingAlpha

3/4/2025

Entering 2024, expectations were that elections and central banks dramatically would affect prices and sentiment in global markets. Each did, especially in the fourth quarter.

Source: SeekingAlpha

3/1/2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics are […]

Source: Yahoo

2/25/2025

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Intra-Cellular Therapies, Inc. to Johnson & Johnson...

Source: Finnhub

2/24/2025

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular...

Source: Finnhub

2/24/2025

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

Source: Yahoo

2/24/2025

BEDMINSTER - Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced its...

Source: Finnhub

2/21/2025

Intra-Cellular (ITCI) delivered earnings and revenue surprises of -220% and 3.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

2/21/2025

On a per-share basis, the Bedminster, New Jersey-based company said it had a loss of 16 cents. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share.

Source: Yahoo